PP30 

PP30 is a potent, selective, ATP-competitive mTOR inhibitor with an IC₅₀ of 80 nM. PP30 blocks insulin-stimulated phosphorylation of Akt at residues S473 and T308, preventing the full activation of Akt. PP30 is applicable for cancer research^[1].

PP30 is a selective mTOR active-site inhibitor with an in vitro IC₅₀ value of 80 nM, and it exhibits only extremely weak activity against other members of the PI3K family as well as some protein kinases including PKCα and PKCβ^[1].
PP30 (0.04-10 μM; pre-incubated prior to insulin stimulation) inhibits insulin-induced phosphorylation of Akt at the S⁴⁷³ and T³⁰⁸ sites in L6 myotubes, with a stronger inhibitory potency against phosphorylation at the S⁴⁷³ site^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

381.45

C₁₈H₁₉N₇OS

1092788-09-4

Solid

White to off-white

NC1=C2C(N(C(C)C)N=C2C3=CC(C(NC4=NCCS4)=O)=CC=C3)=NC=N1

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Feldman ME, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7(2):e38.  [Content Brief]